NAFLD/NASH also results in increased inflammatory markers in the plasma (e.g., IL-6 (Wieckowska et al., 2008), IL-8 (du Plessis et al., 2015; Jamali et al., 2016), TNFα, ICAM-1 and VCAM-1 (Wieckowska et al., 2008; du Plessis et al., 2015; Jamali et al., 2016; Sookoian et al., 2010). This evidence concerns the gene TNF and metabolic dysfunction-associated steatohepatitis.